Kisspeptin-10 vs gonadorelin: evidence, cost, and legality

Which is better, kisspeptin-10 or gonadorelin?

Gonadorelin wins on evidence and on regulatory status. Its human evidence includes a 2018 meta-analysis of 35 studies (1,002 women) for pulsatile GnRH in hypothalamic amenorrhea and a 42 patient series in hypogonadotropic men, and because it was a component of the discontinued FDA approved products Factrel and Lutrepulse a 503A pharmacy can compound it under a prescription. Kisspeptin-10 has physiology studies in groups of 4 to 15 healthy volunteers, no study of any clinical endpoint, and has been in FDA Category 2 since September 29, 2023, which leaves no lawful route to obtain it. The caveat is that the most common real world use of gonadorelin, intermittent injections 2 to 3 times a week alongside testosterone, has no published study either. [1] [3] [5] [7] [9] [10]

How do kisspeptin-10 and gonadorelin compare?

Kisspeptin-10 and Gonadorelin compared by dimension
Dimension	Kisspeptin-10	GonadorelinFavored
Evidence grade [1] [3] [5] [6] [7]	Human observational. Intravenous and subcutaneous physiology studies in healthy men and women (n = 4 to 5 per group in 2011) and a 2026 randomized, single-blind study in 15 healthy men that measured hormone levels, not a clinical outcome.	Human observational. A 2018 systematic review and meta-analysis of 35 studies (1,002 women) of pulsatile GnRH in hypothalamic amenorrhea, a 25 year single center cohort, and a 42 patient series in hypogonadotropic men.
Note: Neither peptide has a randomized trial with a clinical endpoint such as pregnancy or testosterone normalization in a patient population.
Direct comparison [2]	In a crossover physiology study in healthy men, intravenous kisspeptin-10 stimulated LH and FSH with a different time profile from GnRH.	In the same study, intravenous GnRH (gonadorelin) stimulated LH and FSH; all three peptides tested (kisspeptin-10, kisspeptin-54, GnRH) raised gonadotropins.
Note: This is the only direct comparison and it measured hormone responses in healthy volunteers, not a treatment outcome.
Mechanism [1] [8]	Binds KISS1R on hypothalamic GnRH neurons and triggers endogenous pulsatile GnRH release, one step upstream of the pituitary. Circulating half-life of minutes; continuous exposure can desensitize the response.	Is GnRH itself. Binds GnRH receptors on pituitary gonadotrophs to release LH and FSH. Plasma half-life about 2 to 4 minutes; continuous or high dose exposure downregulates the receptor and suppresses gonadotropins.
Clinical uses with evidence [4] [5] [7] [10]	None. No study has tested kisspeptin-10 for fertility, hypogonadism, or sexual function. The one randomized trial in a patient population (men with hypoactive sexual desire disorder) used kisspeptin-54, not kisspeptin-10.	Ovulation induction in hypothalamic amenorrhea and spermatogenesis induction in hypogonadotropic hypogonadism, both by pulsatile pump. Single dose diagnostic testing of pituitary LH response (former Factrel label).
Regulatory status [9] [10] [11]	Not FDA approved. Placed on the FDA 503A Category 2 list on September 29, 2023, citing immunogenicity risk, peptide impurities, and limited safety information. Still in Category 2 as of the FDA page current to April 22, 2026, and not among the peptides reviewed by the advisory committee in July 2026.	Active ingredient of two FDA approved human products (Factrel and Lutrepulse), both discontinued for commercial rather than safety reasons. As a component of approved drugs it is eligible for 503A compounding and is not on the Category 2 list.
Lawful access in the United States [9] [11]	None outside a clinical trial. Products sold as research chemicals are not lawful for human use and are not verified for purity.	Prescription filled by a 503A compounding pharmacy, usually through testosterone telehealth clinics, or pump therapy through a reproductive endocrinology clinic.
Typical cost [9] [11]	Not available through licensed channels.	Compounded gonadorelin through telehealth testosterone clinics typically runs 50 to 150 USD per month.
Side effects [1] [3] [5] [10]	No adverse effects reported in short research protocols in healthy volunteers. Continuous exposure can suppress gonadotropins. No long term human safety data.	Injection or infusion site reactions, headache, nausea, flushing, rare hypersensitivity including anaphylaxis, antibody formation with prolonged use, ovarian hyperstimulation and multiple pregnancy in women, and paradoxical suppression of LH and FSH if given continuously.
WADA status [12]	Prohibited (non-approved substance under S0 and a hormone modulator under S2).	Prohibited in male athletes under S2 (GnRH and its analogs).

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Kisspeptin-10 and Gonadorelin: grade, status, and cost
Attribute	Kisspeptin-10	Gonadorelin
Class	Ten amino acid C-terminal fragment of kisspeptin (KISS1 gene product), an agonist at the kisspeptin receptor (KISS1R, formerly GPR54)	Synthetic decapeptide identical to native human gonadotropin-releasing hormone
What it is	Fragment of a brain hormone that raises LH and testosterone in small human studies; still on FDA's 503A Category 2 safety risk list, so it cannot be compounded.	Native GnRH: proven when pumped in pulses for hypothalamic infertility, unstudied as the 2 to 3 times weekly TRT add-on clinics now sell.
Evidence	Evidence: Human observational evidence	Evidence: Human observational evidence
FDA status	Regulatory: Not eligible for compounding	Regulatory: FDA approved
Compounding	FDA placed kisspeptin-10 on the 503A Category 2 list (substances that may present significant safety risks) on September 29, 2023, citing immunogenicity risk, peptide impurities, and no or limited safety information. As of the FDA page current to April 22, 2026, kisspeptin-10 remains in Category 2 and was not among the peptides withdrawn in April 2026 or taken up by the Pharmacy Compounding Advisory Committee in July 2026. It is not an FDA approved drug and a 503A pharmacy may not compound it.	Gonadorelin was the active ingredient of two FDA approved human products, Factrel (gonadorelin hydrochloride, a diagnostic for pituitary function) and Lutrepulse (gonadorelin acetate for pump delivered ovulation induction), both of which have been discontinued in the United States for commercial rather than safety reasons. Because it is a component of FDA approved drugs, 503A pharmacies can compound it under a prescription, which is why it is widely available as a compounded testosterone therapy adjunct. As a 10 amino acid peptide it was not affected by the March 2020 transition of hCG and other large proteins to biologic status, so it filled the gap when compounded hCG became unavailable. It is not on the FDA Category 2 list. The currently marketed FDA approved gonadorelin products are veterinary.
WADA	WADA: WADA prohibited	WADA: WADA prohibited
Routes	Intravenous bolus or infusion (research studies), Subcutaneous bolus or pump infusion (research studies), Subcutaneous injection vials (as sold, not lawful for human use)	Subcutaneous or intravenous pulsatile infusion by portable pump (evidence based use), Single subcutaneous or intravenous injection for pituitary function testing (former diagnostic use), Intermittent subcutaneous injections 2 to 3 times weekly (compounded TRT adjunct, no studies)
Typical cost	Not available through licensed channels. Research chemical sellers list it, but those products are not lawful for human use and are not verified for purity.	Compounded gonadorelin is usually priced per vial: 50 USD per vial as an add-on in a telehealth testosterone program whose fee is separate. Pulsatile pump therapy for infertility is delivered through reproductive endocrinology clinics, where the drug is a small part of the total cost of treatment. Prices checked 2026-09-22 on published provider and pharmacy price pages.
Last verified	Sep 22, 2026	Sep 23, 2026

Has kisspeptin-10 been tested directly against gonadorelin?

Direct comparisons of Kisspeptin-10 and Gonadorelin
Study	Design and population	Outcome	Grade
Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men2015 PMID 26089302	Crossover physiology study of intravenous kisspeptin-10, kisspeptin-54, and GnRHHealthy men	All three peptides stimulated LH and FSH; the time profiles of the gonadotropin responses differed by peptide	Evidence: Human observational evidence

What do kisspeptin-10 and gonadorelin cost?

Typical cost of Kisspeptin-10 and Gonadorelin
Dimension	Kisspeptin-10	Gonadorelin
Typical cost	Not available through licensed channels. Research chemical sellers list it, but those products are not lawful for human use and are not verified for purity.	Compounded gonadorelin is usually priced per vial: 50 USD per vial as an add-on in a telehealth testosterone program whose fee is separate. Pulsatile pump therapy for infertility is delivered through reproductive endocrinology clinics, where the drug is a small part of the total cost of treatment. Prices checked 2026-09-22 on published provider and pharmacy price pages.
Price detail	Kisspeptin-10 price by channel	Gonadorelin price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Which one has better evidence, kisspeptin-10 or gonadorelin?

Gonadorelin. Pulsatile GnRH has a 2018 meta-analysis of 35 studies in 1,002 women with hypothalamic amenorrhea and a 42 patient series in hypogonadotropic men in which it induced sperm in 54 of 57 treatment courses. Kisspeptin-10 has physiology studies in healthy volunteers that measured LH, FSH, and testosterone and no study of a clinical endpoint. [1] [3] [5] [7]

Can I get kisspeptin-10 from a compounding pharmacy?

No. FDA placed kisspeptin-10 on the 503A Category 2 list in September 2023 and it remains there as of the page current to April 22, 2026, which means a 503A pharmacy may not compound it. Gonadorelin, by contrast, is a component of formerly approved FDA drugs and can be compounded under a prescription. [9] [10] [11]

Is either one proven as an add-on to testosterone therapy?

No. There is no published study of intermittent subcutaneous gonadorelin injections 2 to 3 times per week as a testosterone therapy adjunct, and kisspeptin-10 has never been tested in that setting. Gonadorelin's evidence is for pulsatile pump delivery every 60 to 120 minutes. [3] [5] [8]

How do they differ in mechanism?

Kisspeptin-10 acts on KISS1R on hypothalamic GnRH neurons and makes the body release its own GnRH in pulses. Gonadorelin is GnRH and acts directly on the pituitary. Both have half-lives of minutes and both lose effect with continuous exposure, which is why chronic protocols use pulses or intermittent infusions. [1] [3] [8]

Are they allowed in sport?

Neither is allowed. Gonadorelin is prohibited in male athletes under WADA section S2 as a GnRH analog, and kisspeptin-10 is prohibited as a non-approved substance under S0 and as a hormone modulator. [12]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Kisspeptin-10 vs gonadorelin: evidence, cost, and legality. https://peptideagent.ai/compare/kisspeptin-10-vs-gonadorelin
HTML link: <a href="https://peptideagent.ai/compare/kisspeptin-10-vs-gonadorelin">Kisspeptin-10 vs gonadorelin: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Kisspeptin-10 vs gonadorelin

The short answer